Judging the efficacy of anti-psychotics is complex, and the leading studies typically give little if any close attention to subjective experience. Some studies of antipsychotic treatment of first-episode psychosis show up to 90% efficacy rates by 12 months, judged in terms of symptom reduction (
Lieberman, J. A. et al.,
“Time Course and Biologic Correlates of Treatment Response in First Episode Schizophrenia,” Archives of General Psychiatry 50, no. 5 (1993): 369–376). However, rates of discontinuation of medication – whether due to intolerability of effects or inefficacy in satisfactorily altering symptoms or other reasons – are as high as 50% (
Cotton, S. M. et al., “Gender Differences in Premorbid, Entry, Treatment, and Outcome Characteristics in a Treated Epidemiological Sample of 661 Patients with First Episode Psychosis,” Schizophrenia Research 114, No. 1-3 [2009]: 17–24;
Crossley, N. A. et al., “Efficacy of Atypical v. Typical Antipsychotics in the Treatment of Early Psychosis: Meta-Analysis,” British Journal of Psychiatry 196, no. 6 [2010]: 434–439, at 434
). Moreover, antipsychotics have fewer symptom reducing effects among persons with chronic conditions, and discontinuation rates are even higher among this population (
Lieberman, J. A. et al., “Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia,” New England Journal of Medicine
353,
no. 12 (2005):
1209–
1223). On the lack of clear advances in efficacy among new generation (atypical) antipsychotics, see
McDonagh, M. et al., Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report (
Portland, OR:
Oregon Health & Science University, 2010) (original report January 2005; Update 1 April 2006; Update 2 May 2008; Update 3 July 2010),
available at <
http://derp.ohsu.edu/about/final-document-display.cfm> (last visited February 1,
2013) [hereinafter cited as
Drug Class Review].
Google Scholar